Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1

Status

Completed 2Terminated 1

Sponsor Class

OTHER 35INDUSTRY 13NETWORK 5NIH 3

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 3Head & Neck 1

Conditions

Prostatic Neoplasms 3

Interventions

Magnetic Resonance Spectroscopy 54Specimen Handling 48aldesleukin 35Docetaxel 30Biopsy 28Bevacizumab 24Gemcitabine 21Cyclophosphamide 21Cisplatin 21Radiotherapy 19Prednisone 17Sorafenib 16Carboplatin 16sargramostim 15PROSTVAC 15Paclitaxel 14Interferon-alpha 14Sunitinib 13ixabepilone 12cabozantinib 12Immunoglobulin G 12Goserelin 12Disulfides 12fludarabine phosphate 11fludarabine 11Nivolumab 11Fluorouracil 11Chemotherapy, Adjuvant 11pembrolizumab 10bicalutamide 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
NIH × luprolide acetate gel depot × Genitourinary × Clear all
NCT01163084 2019-02-28

Leuprolide Acetate or Goserelin Acetate With or Without Vismodegib Followed by Surgery in Treating Patients With Locally Advanced Prostate Cancer

National Cancer Institute (NCI)

Phase 1/2 Terminated
10 enrolled 7 charts
Genitourinary

Prostatic Neoplasms

NCT01120236 2018-02-26

Bicalutamide and Goserelin or Leuprolide Acetate With or Without Cixutumumab in Treating Patients With Newly Diagnosed Metastatic Prostate Cancer

National Cancer Institute (NCI)

Phase 2 Completed
211 enrolled 17 charts
Genitourinary

Prostatic Neoplasms

NCT00589472 2017-10-06

TARGET

National Cancer Institute (NCI)

Phase 2 Completed
19 enrolled 12 charts
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡